CTOs on the Move

TLC Laser Eye Centers

www.tlcvision.com

 
TLC Laser Eye Centers is North America’s leading laser eye surgery provider, with more than 20 years of LASIK experience. Book a Free Consultation near you.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tlcvision.com
  • 5280, Solar Drive
    Mississauga, ON CAN L4W 5M8
  • Phone: 877.852.2020

Executives

Name Title Contact Details

Similar Companies

MK Education

MK Education is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mayne Pharma

Mayne Pharma is a fast growing company, focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, with operations in Australia and the US. The Company has grown substantially and reflects the hard work and de...

Tanabe Research Laboratories U.S.A.

Tanabe Research Laboratories U.S.A., Inc. (TRL), is a wholly owned subsidiary of Tanabe Seiyaku Co., Ltd., headquartered in Osaka, Japan. The Research staff of TRL are highly skilled in biology and/or chemistry and at working in a collaborative

RSA Americas

RSA Americas is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Savara Pharmaceuticals

Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.